Naltrexone in Compulsive Sexual Behavior Disorder : A Feasibility Study of Twenty Men
Copyright © 2020 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Compulsive sexual behavior disorder (CSBD) is a common disorder affecting different areas of life, although studies focusing on pharmacological treatment are sparse.
AIM: To investigate whether the opioid receptor antagonist naltrexone is feasible and tolerable and can provide symptom reduction in CSBD.
METHODS: Twenty men aged 27-60 years (mean = 38.8 years, standard deviation = 10.3) with CSBD seeking treatment in an outpatient nonforensic clinic received four weeks of naltrexone 25-50 mg. Measurements were made before, during, and four weeks after treatment.
OUTCOMES: The self-assessment Hypersexual Disorder: Current Assessment Scale (HD: CAS) score was the primary outcome measure, and secondary outcomes were the Hypersexual Behavior Inventory (HBI) score, reported adverse effects, adherence to treatment, and dropouts.
RESULTS: There was significant decrease on both HD: CAS and HBI scores during treatment with naltrexone. Even though some of the effects remained after treatment, the increased scores on HD: CAS indicated worsening of CSBD symptoms. The most reported side effects were fatigue (55%), nausea (30%), vertigo (30%), and abdominal pain (30%). However, there were no serious adverse effects leading to discontinuation of naltrexone.
CLINICAL IMPLICATIONS: Despite side effects being common, naltrexone seems to be feasible in the treatment of CSBD.
STRENGTHS & LIMITATIONS: Being the first nonforensic prospective trial on naltrexone in CSBD, this study provides novel insights on a pharmacological intervention. However, owing to the small sample size and the lack of a control group, conclusions of effectiveness should be interpreted with caution.
CONCLUSION: Naltrexone is feasible and tolerable and may reduce symptoms of CSBD; nevertheless, future studies should ensure a randomized controlled procedure to evaluate possible effectiveness. Savard J, Öberg KG, Chatzittofis A, et al. Naltrexone in Compulsive Sexual Behavior Disorder: A Feasibility Study of Twenty Men. J Sex Med 2020;17:1544-1552.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
---|---|
Enthalten in: |
The journal of sexual medicine - 17(2020), 8 vom: 15. Aug., Seite 1544-1552 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Savard, Josephine [VerfasserIn] |
---|
Links: |
---|
Themen: |
5S6W795CQM |
---|
Anmerkungen: |
Date Completed 21.12.2020 Date Revised 31.05.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.jsxm.2020.04.318 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM311118402 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM311118402 | ||
003 | DE-627 | ||
005 | 20231225141555.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.jsxm.2020.04.318 |2 doi | |
028 | 5 | 2 | |a pubmed24n1037.xml |
035 | |a (DE-627)NLM311118402 | ||
035 | |a (NLM)32532705 | ||
035 | |a (PII)S1743-6095(20)30535-X | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Savard, Josephine |e verfasserin |4 aut | |
245 | 1 | 0 | |a Naltrexone in Compulsive Sexual Behavior Disorder |b A Feasibility Study of Twenty Men |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 21.12.2020 | ||
500 | |a Date Revised 31.05.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2020 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved. | ||
520 | |a BACKGROUND: Compulsive sexual behavior disorder (CSBD) is a common disorder affecting different areas of life, although studies focusing on pharmacological treatment are sparse | ||
520 | |a AIM: To investigate whether the opioid receptor antagonist naltrexone is feasible and tolerable and can provide symptom reduction in CSBD | ||
520 | |a METHODS: Twenty men aged 27-60 years (mean = 38.8 years, standard deviation = 10.3) with CSBD seeking treatment in an outpatient nonforensic clinic received four weeks of naltrexone 25-50 mg. Measurements were made before, during, and four weeks after treatment | ||
520 | |a OUTCOMES: The self-assessment Hypersexual Disorder: Current Assessment Scale (HD: CAS) score was the primary outcome measure, and secondary outcomes were the Hypersexual Behavior Inventory (HBI) score, reported adverse effects, adherence to treatment, and dropouts | ||
520 | |a RESULTS: There was significant decrease on both HD: CAS and HBI scores during treatment with naltrexone. Even though some of the effects remained after treatment, the increased scores on HD: CAS indicated worsening of CSBD symptoms. The most reported side effects were fatigue (55%), nausea (30%), vertigo (30%), and abdominal pain (30%). However, there were no serious adverse effects leading to discontinuation of naltrexone | ||
520 | |a CLINICAL IMPLICATIONS: Despite side effects being common, naltrexone seems to be feasible in the treatment of CSBD | ||
520 | |a STRENGTHS & LIMITATIONS: Being the first nonforensic prospective trial on naltrexone in CSBD, this study provides novel insights on a pharmacological intervention. However, owing to the small sample size and the lack of a control group, conclusions of effectiveness should be interpreted with caution | ||
520 | |a CONCLUSION: Naltrexone is feasible and tolerable and may reduce symptoms of CSBD; nevertheless, future studies should ensure a randomized controlled procedure to evaluate possible effectiveness. Savard J, Öberg KG, Chatzittofis A, et al. Naltrexone in Compulsive Sexual Behavior Disorder: A Feasibility Study of Twenty Men. J Sex Med 2020;17:1544-1552 | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Compulsive sexual behavior disorder | |
650 | 4 | |a Hypersexual disorder | |
650 | 4 | |a Naltrexone | |
650 | 4 | |a Sexual addiction | |
650 | 7 | |a Naltrexone |2 NLM | |
650 | 7 | |a 5S6W795CQM |2 NLM | |
700 | 1 | |a Öberg, Katarina Görts |e verfasserin |4 aut | |
700 | 1 | |a Chatzittofis, Andreas |e verfasserin |4 aut | |
700 | 1 | |a Dhejne, Cecilia |e verfasserin |4 aut | |
700 | 1 | |a Arver, Stefan |e verfasserin |4 aut | |
700 | 1 | |a Jokinen, Jussi |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t The journal of sexual medicine |d 2004 |g 17(2020), 8 vom: 15. Aug., Seite 1544-1552 |w (DE-627)NLM159924006 |x 1743-6109 |7 nnns |
773 | 1 | 8 | |g volume:17 |g year:2020 |g number:8 |g day:15 |g month:08 |g pages:1544-1552 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jsxm.2020.04.318 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 17 |j 2020 |e 8 |b 15 |c 08 |h 1544-1552 |